Navigation Links
Generics Analysis: Key Patent Case Reviews
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generics Analysis: Key Patent Case Reviews

http://www.reportlinker.com/p0968573/Generics-Analysis-Key-Patent-Case-Reviews.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolioCelgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016–27.In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.Gain clarity on when Cymbalta and Revlimid are likely to face generic competitionAssess the threat to Eli Lilly and Celgene of these products' genericization

 

GENERIC ENTRY TIMING REVIEWS•Key findings

•Cymbalta (duloxetine; Eli Lilly) - EU launch of generic Cymbalta from August 2014

•Revlimid (lenalidomide; Celgene) - Natco sued for infringement of 14 patents

 

APPENDIX•References

•Exchange rates

 

TABLES

•Table: Cymbalta: patent protection and exclusivity in Europe

•Table: Revlimid: patent protection and exclusivity in the US

•Table: Exchange rates, 2012

 

FIGURES

•Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002–17

•Figure: Revlimid and total Celgene sales, 2002–17

•Figure: US patent and exclusivity timeline relating to Revlimid

•Figure: Chemical structure of lenalidomide

 

Companies Mentioned

Devoteam SA, Hutchison 3G UK Limited

 

To order this report:

Drug_and_Medication Industry: Generics Analysis: Key Patent Case Reviews

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
3. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
4. Branded Generics in South East Asia: Current and Future Opportunities
5. Essential Medical Dismisses Patent Case against Masimo and Cercacor
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Broad Patent Protection Granted for iBio Immunomodulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... PHILADELPHIA , July 15, 2017 Enterin Inc., ... compounds to treat Parkinson,s disease (PD), today announced the completion ... included new investors New Ventures III, as well as the ... "We are absolutely thrilled to have the support of New ... of our investors as validation of the potential of our ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... use of violence and aggression to solve problems and pleads with world leaders to be ... armed forces do not bring peace. He says there is a peaceful and positive way ...
(Date:7/21/2017)... ST. LOUIS, MO (PRWEB) , ... July 21, 2017 , ... ... are born knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. ... created the Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is ... clips in the FCPX timeline. This effect isolates horizontal and vertical lines of pixels ... contains either a rotating or flipping animation and can be changed using a drop-down ...
Breaking Medicine News(10 mins):